Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

Abstract

Discontinuation due to adverse effects in the absence of macrovascular invasion, extrahepatic metastases, and deteriorated PS predicts the best PSS in compensated patients, thereby setting the stage for both improved patient counseling and selection for second-line therapy.